Amneal Announces European Approval of Adcomfo® (Omalizumab), a Biosimilar to XOLAIR®
Amneal announced that the European Commission granted marketing authorization for Adcomfo® (omalizumab), a biosimilar to XOLAIR®.
Why it matters — The authorization is a regulatory milestone for Amneal’s biosimilar product in Europe.